search
Back to results

Hmong Microbiome ANd Gout, Obesity, Vitamin C (HMANGO-C)

Primary Purpose

Hyperuricemia, Gout

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Vitamin C
Sponsored by
University of Minnesota
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hyperuricemia

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Self-identified Hmong persons whose both parents are Hmong, with and without hyperuricemia (serum urate (UA) ≥ 6.8 mg/dL ) and/or gout (defined by 2020 American College of Rheumatology Guideline for the Management of Gout) are eligible for the study.
  • For those with gout, participants qualify if they have serum UA ≥ 6.8 mg/dL based on the baseline measurement or serum UA < 6.8 mg/dL based on the baseline measurement with at least 1 episode of peripheral joint or bursal swelling, pain, or tenderness (acute gout flare) in their lifetime, (with or without urate-lowering therapy)

Exclusion Criteria:

  • Allergy or sensitivity to vitamin C
  • Diagnosis/history of:

    • Gastrointestinal surgery including colectomy, ileectomy, and gastrectomy
    • Inflammatory bowel disease
    • Auto-immune disease
    • Type I diabetes mellitus
    • Severe kidney disease (i.e., on dialysis)
    • End-stage liver disease (i.e. cirrhosis)
    • Glucose-6-phosphate dehydrogenase deficiency, (due to increased bleeding risk in those with G6PD deficiency when receiving vitamin C)
  • Pregnant or breastfeeding persons
  • Current use of:

    • Antibiotics
    • Probiotics supplement
    • Ketogenic diet

Sites / Locations

  • University of Minnesota

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Active Comparator

Arm Label

People with hyperuricemia (HU) or gout without urate-lowering therapy (ULT)

People with hyperuricemia (HU) or gout with urate-lowering therapy (ULT)

People without hyperuricemia (HU) or gout without urate-lowering therapy (ULT)

Arm Description

Participants with HU or gout who are not treated with ULT will take 500 mg of vitamin C twice daily for 8 weeks.

Participants with HU or gout who are treated with ULT will take 500 mg of vitamin C twice daily for 8 weeks.

Participants without HU or gout who are not treated with ULT will take 500 mg of vitamin C twice daily for 8 weeks.

Outcomes

Primary Outcome Measures

Change in serum urate
Serum urate levels (mg/dL) will be measured from baseline to end, and the absolute difference will be reported.

Secondary Outcome Measures

Change in Gout Assessment Questionnaire 2.0 score
The Gout Assessment Questionnaire 2.0 (GAQ2.0) contains 25 items covering the following domains: gout overall concern, medication side effects, perception of unmet needs, wellbeing during acute gout attack, and concerns during gout attack. Items are rated on a 5-point likert scale. Total scores range from 25 to 125 with higher scores indicating more gout symptoms.
Change in body mass index (BMI)
Change in body mass index (BMI) from baseline to end. BMI is calculated as body weight (in kg) divided by height (in cm) squared. BMI is reported in kg/m^2, and the change will be reported as an absolute value.
Change in Swollen Joint Count (44 Joints)
Change in gout-related symptoms will be measured from baseline to end using the Swollen Joint Count (44 Joints) post-administration of vitamin C. Scores range from 0-44 with higher scores indicating more swollen joints.

Full Information

First Posted
June 14, 2021
Last Updated
September 6, 2023
Sponsor
University of Minnesota
search

1. Study Identification

Unique Protocol Identification Number
NCT04938024
Brief Title
Hmong Microbiome ANd Gout, Obesity, Vitamin C (HMANGO-C)
Official Title
Hmong Microbiome ANd Gout, Obesity, Vitamin C (HMANGO-C)
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Completed
Study Start Date
March 28, 2021 (Actual)
Primary Completion Date
August 30, 2023 (Actual)
Study Completion Date
August 30, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Minnesota

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Investigators seek to quantify the impact of vitamin C on patient outcomes, including serum urate level, gout-related symptoms, and obesity (measured by BMI) in both healthy Hmong adults and in Hmong patients with hyperuricemia (HU) and/or gout; identify associations between individuals' taxonomic and functional patterns of gut microbiota and its impact on the serum urate-lowering effect of vitamin C; compare taxonomic and functional patterns of gut microbiota between people with HU and/or gout and people without HU and gout; and identify associations between individuals' taxonomic and functional patterns of gut microbiota and self-reported acute gout trigger foods.
Detailed Description
Gout, caused by chronic elevation of serum urate (SU), is the most common form of inflammatory arthritis worldwide. About 3.9% of adults in the U.S. suffer from gout and prevalence is even higher in certain ethnicities. Factors that may influence SU include patients' characteristics (gender, weight, renal function, etc.), genetics, and diet. Foods and beverages that have shown positive association with HU and gout are alcohol (particularly beer), purine-rich foods, red meat, seafood, and sugar-sweetened drinks, while inverse association has been found with dairy intake such as skimmed milk and low-calorie yoghurt, coffee and vitamin C. The gut microbiota composition and function have been linked to common chronic human disorders, such as obesity, diabetes, non-alcoholic fatty liver disease, and rheumatoid arthritis. Intestinal microbiota of gout patients were also found highly distinct from healthy individuals in both organismal and functional structures from a small study conducted in China. Strategies to use personal microbiome features to predict glucose response to specific food have been proposed. However, little is known about the impact of microbiota on food and urate-lowering therapy (ULT). The translational significance of a microbiota-guided approach to select appropriate foods and medications that could prevent the elevation of SU for individuals with gout or at high risk for gout is significant. The Hmong are a unique Asian sub-population. Hmong men exhibit a 2-fold higher prevalence of gout, manifesting it earlier in life and experiencing up to 5-fold increased risk of gout-associated complications, compared to non-Hmong in the US. This could lead to higher rates of cardiometabolic diseases (e.g. hypertension, renal disease, type 2 diabetes [T2DM]), which significantly impact morbidity, mortality and healthcare costs. Accordingly, the investigators seek to quantify the impact of vitamin C on patient outcomes, including serum urate level, gout-related symptoms, and obesity (measured by BMI) in both healthy Hmong adults and in Hmong patients with hyperuricemia (HU) and/or gout; identify associations between individuals' taxonomic and functional patterns of gut microbiota and its impact on the serum urate-lowering effect of vitamin C; compare taxonomic and functional patterns of gut microbiota between people with HU and/or gout and people without HU and gout; and identify associations between individuals' taxonomic and functional patterns of gut microbiota and self-reported acute gout trigger foods.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hyperuricemia, Gout

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
135 (Actual)

8. Arms, Groups, and Interventions

Arm Title
People with hyperuricemia (HU) or gout without urate-lowering therapy (ULT)
Arm Type
Experimental
Arm Description
Participants with HU or gout who are not treated with ULT will take 500 mg of vitamin C twice daily for 8 weeks.
Arm Title
People with hyperuricemia (HU) or gout with urate-lowering therapy (ULT)
Arm Type
Experimental
Arm Description
Participants with HU or gout who are treated with ULT will take 500 mg of vitamin C twice daily for 8 weeks.
Arm Title
People without hyperuricemia (HU) or gout without urate-lowering therapy (ULT)
Arm Type
Active Comparator
Arm Description
Participants without HU or gout who are not treated with ULT will take 500 mg of vitamin C twice daily for 8 weeks.
Intervention Type
Dietary Supplement
Intervention Name(s)
Vitamin C
Other Intervention Name(s)
L-ascorbic acid
Intervention Description
Vitamin C is a commercially available over-the-counter food supplement.
Primary Outcome Measure Information:
Title
Change in serum urate
Description
Serum urate levels (mg/dL) will be measured from baseline to end, and the absolute difference will be reported.
Time Frame
8 weeks
Secondary Outcome Measure Information:
Title
Change in Gout Assessment Questionnaire 2.0 score
Description
The Gout Assessment Questionnaire 2.0 (GAQ2.0) contains 25 items covering the following domains: gout overall concern, medication side effects, perception of unmet needs, wellbeing during acute gout attack, and concerns during gout attack. Items are rated on a 5-point likert scale. Total scores range from 25 to 125 with higher scores indicating more gout symptoms.
Time Frame
8 weeks
Title
Change in body mass index (BMI)
Description
Change in body mass index (BMI) from baseline to end. BMI is calculated as body weight (in kg) divided by height (in cm) squared. BMI is reported in kg/m^2, and the change will be reported as an absolute value.
Time Frame
8 weeks
Title
Change in Swollen Joint Count (44 Joints)
Description
Change in gout-related symptoms will be measured from baseline to end using the Swollen Joint Count (44 Joints) post-administration of vitamin C. Scores range from 0-44 with higher scores indicating more swollen joints.
Time Frame
8 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Self-identified Hmong persons whose both parents are Hmong, with and without hyperuricemia (serum urate (UA) ≥ 6.8 mg/dL ) and/or gout (defined by 2020 American College of Rheumatology Guideline for the Management of Gout) are eligible for the study. For those with gout, participants qualify if they have serum UA ≥ 6.8 mg/dL based on the baseline measurement or serum UA < 6.8 mg/dL based on the baseline measurement with at least 1 episode of peripheral joint or bursal swelling, pain, or tenderness (acute gout flare) in their lifetime, (with or without urate-lowering therapy) Exclusion Criteria: Allergy or sensitivity to vitamin C Diagnosis/history of: Gastrointestinal surgery including colectomy, ileectomy, and gastrectomy Inflammatory bowel disease Auto-immune disease Type I diabetes mellitus Severe kidney disease (i.e., on dialysis) End-stage liver disease (i.e. cirrhosis) Glucose-6-phosphate dehydrogenase deficiency, (due to increased bleeding risk in those with G6PD deficiency when receiving vitamin C) Pregnant or breastfeeding persons Current use of: Antibiotics Probiotics supplement Ketogenic diet
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Robert J Straka, PharmD, FCCP
Organizational Affiliation
Univeristy of Minnesota Department of Experimental and Clinical Pharmacology
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Minnesota
City
Minneapolis
State/Province
Minnesota
ZIP/Postal Code
55455
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Hmong Microbiome ANd Gout, Obesity, Vitamin C (HMANGO-C)

We'll reach out to this number within 24 hrs